The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease
Open accessAbstract
BACKGROUND: Ezetimibe lowers plasma levels of low-density lipoprotein (LDL) cholesterol by inhibiting the activity of the Niemann-Pick C1-like 1 (NPC1L1) protein. However, whether such inhibition reduces the risk of coronary heart disease is not known. Human mutations that inactivate a gene encoding a drug target can mimic the action of an inhibitory drug and thus can be used to infer potential effects of that drug. METHODS: We sequenced the exons of NPC1L1 in 7364 patients with coronary heart disease and in 14,728 controls without such disease who were of European, African, or South Asian ancestry. We identified carriers of inactivating mutations (nonsense, splice-site, or frameshift mutations). In addition, we genotyped a specific inactivating mutation (p.Arg406X) in 22,590 patients with coronary heart disease and in 68,412 controls. We tested the association between the presence of an inactivating mutation and both plasma lipid levels and the risk of coronary heart disease. RESULTS: With sequencing, we identified 15 distinct NPC1L1 inactivating mutations; approximately 1 in every 650 persons was a heterozygous carrier for 1 of these mutations. Heterozygous carriers of NPC1L1 inactivating mutations had a mean LDL cholesterol level that was 12 mg per deciliter (0.31 mmol per liter) lower than that in noncarriers (P=0.04). Carrier status was associated with a relative reduction of 53% in the risk of coronary heart disease (odds ratio for carriers, 0.47; 95% confidence interval, 0.25 to 0.87; P=0.008). In total, only 11 of 29,954 patients with coronary heart disease had an inactivating mutation (carrier frequency, 0.04%) in contrast to 71 of 83,140 controls (carrier frequency, 0.09%). CONCLUSIONS: Naturally occurring mutations that disrupt NPC1L1 function were found to be associated with reduced plasma LDL cholesterol levels and a reduced risk of coronary heart disease. (Funded by the National Institutes of Health and others.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A genetic sequencing study involving more than 90,000 patients found significantly lower LDL-C levels and a lower risk of coronary heart diseases among patients with NPC1L1 mutations [58]”
From Established and Emerging Lipid-Lowering Drugs for Primary and Secondary Cardiovascular Prevention (2023) · cites this paper as [58]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Polymorphisms affecting NPC1L1 are associated with both lower levels of LDL cholesterol and a lower risk of cardiovascular events.19”
From Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes (2015) · cites this paper as [19]
Experimental — accuracy not yet measuredIn the citing paper
“There is no clear evidence that statins have a clinically significant beneficial or adverse effect on renal function [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“A systematic review of the benefits and harms of statins in patients with a functioning kidney transplant included 3465 patients, free of CHD, from 22 studies. Although the authors concluded that statins may reduce CV events, they also suggested a need for additional studies [253].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [253]
In the citing paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [245]
In the citing paper
“Similarly, a lifelong reduction of only 11% in plasma LDL-cholesterol levels due to loss-of-function mutations in NPC1L1, an intestinal cholesterol transporter, causes a striking 53% reduction in myocardial infarction (37).”
From Health Benefits of the Mediterranean Diet: Metabolic and Molecular Mechanisms (2018) · cites this paper as [37]
In the citing paper
“Naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD.245”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [245]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
THE ATHEROSCLEROSIS RISK IN COMMUNIT (ARIC) STUDY: DESIGN AND OBJECTIVES
THE ARIC INVESTIGATORS (1989) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a115184 · Cited by 3,510
Self-citationBiological, clinical and population relevance of 95 loci for blood lipids
Teslovich, T. M., Musunuru, K., Smith, A. V., Edmondson, A. C., Stylianou, I. M., Koseki, M., Pirruccello, J. P., Ripatti, S., Chasman, D. I., Willer, C. J., et al. (2010) · Nature · doi:10.1038/nature09270 · Cited by 3,487
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
(1989) · PubMed · Cited by 3,139
Design of the Women’s Health Initiative Clinical Trial and Observational Study
The Women’s Health Initiative Study Group (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,580
A Randomized Trial of Low-Dose Aspirin in the Primary Prevention of Cardiovascular Disease in Women
Ridker, P. M., Cook, N. R., Lee, I.-M., Gordon, D., Gaziano, J. M., Manson, J. E., Hennekens, C. H., & Buring, J. E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050613 · Cited by 1,945
Niemann-Pick C1 Like 1 Protein Is Critical for Intestinal Cholesterol Absorption
Altmann, S. W., Davis, H. R., Zhu, L.-J., Yao, X., Hoos, L. M., Tetzloff, G. G., Iyer, S. P. N., Maguire, M., Golovko, A., Zeng, M., et al. (2004) · Science · doi:10.1126/science.1093131 · Cited by 1,818
Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease
Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671
Berge, K. E., Tian, H., Graf, G. A., Yu, L., Grishin, N. V., Schultz, J. R., Kwiterovich, P. O., Shan, B., Barnes, R., & Hobbs, H. H. (2000) · Science · doi:10.1126/science.290.5497.1771 · Cited by 1,645
Research works printed but not linked: 2
- Taylor HA, 2005, Ethn Dis, 15, S6
- Ye Z, 2013, Glob Cardiol Sci Pract, 2013, 82
Cited by
Sorted by citations
Items 301–400 of 428
DNA and RNA Molecules as a Foundation of Therapy Strategies for Treatment of Cardiovascular Diseases
Rakicevic, L. B. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15082141 · Cited by 4
Updates on Non-Statin LDL-Lowering Therapy
Abdulla, A., Shalaby, M., Kumfa, P. N., Raja, M. W., Allencherril, J., & Sharifeh, T. A. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02028-3 · Cited by 4
ASGR1 is a promising target for lipid reduction in pigs with PON2 as its inhibitor
Yin, Y., Liu, J., Yu, J., Dong, D., Gao, F., Yu, L., Du, X., & Wu, S. (2024) · iScience · doi:10.1016/j.isci.2024.110288 · Cited by 4
The State of Whole-Genome Sequencing
Dervan, A., & Shendure, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800681-8.00003-7 · Cited by 4
Genotype‐driven NPC1L1 and PCSK9 inhibition and reduced risk of periodontitis
Baumeister, S., Holtfreter, B., Reckelkamm, S. L., Kocher, T., Alayash, Z., Ehmke, B., Baurecht, H., & Nolde, M. (2022) · Journal Of Clinical Periodontology · doi:10.1111/jcpe.13719 · Cited by 4
Majithia, A. R., Altshuler, D., & Hirschhorn, J. N. (2016) · Elsevier eBooks · doi:10.1016/b978-0-323-29738-7.00004-6 · Cited by 4
Epidemiologic Characterization of Risk for Cardiovascular Diseases
Maki, K. C., Dicklin, M. R., & Nieman, K. M. (2018) · Contemporary cardiology · doi:10.1007/978-3-319-97622-8_1 · Cited by 4
Bays, H. E. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.11.006 · Cited by 4
Bioinformatics Principles for Deciphering Cardiovascular Diseases
Shu, L., Arneson, D. V., & Yang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809657-4.99576-0 · Cited by 4
Prabhakar, A. P., Vedamurthy, D., & Kalra, D. K. (2025) · Current Cardiovascular Risk Reports · doi:10.1007/s12170-025-00764-x · Cited by 3
Atherosclerosis: Is a cure in sight?
Wilson, D. P., & Gidding, S. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.06.010 · Cited by 3
Statin Treatment Induced a Lipogenic Expression Hierarchical Network Centered by SREBF2 in the Liver
Song, S., Niu, M., Liang, Q., Wang, L., Min, H., Peng, Y., Wang, H., & Gao, Q. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.573824 · Cited by 3
The pharmacology of cholesterol-lowering drugs: The pharmacology of cholesterol-lowering drugs
Ballantyne, C. M., & Catapano, A. L. (2022) · European Atherosclerosis Journal · doi:10.56095/eaj.v1i1.7 · Cited by 3
From Genetic Findings to new Intestinal Molecular Targets in Lipid Metabolism
May, C. L., Ducheix, S., Cariou, B., & Rimbert, A. (2025) · Current Atherosclerosis Reports · doi:10.1007/s11883-024-01264-w · Cited by 3
NPC1L1 mutations lower CHD risk
Geach, T. (2014) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2014.202 · Cited by 3
Hassan, M. S. (2014) · Global Cardiology Science and Practice · doi:10.5339/gcsp.2014.48 · Cited by 3
Pharmacogenetics of cardiovascular drugs
Saleh, A., Al-Abcha, A. K., & Pereira, N. L. (2023) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000001038 · Cited by 3
Pharmacogenomics of Blood Lipid Regulation
Legault, M., Tardif, J., & Dubé, M. (2018) · Pharmacogenomics · doi:10.2217/pgs-2018-0007 · Cited by 4
Emrich, I. E., Heine, G. H., Schulze, P. C., Rogacev, K. S., Fliser, D., Wagenpfeil, S., Böhm, M., Lütjohann, D., & Weingärtner, O. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.801 · Cited by 3
Brotherhood of genetics and preventive medication: Figure 1
Schunkert, H. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv153 · Cited by 3
Lifelong genetically lowered sclerostin and risk of cardiovascular diseasePreprint
Bovijn, J., Krebs, K., Chen, C., Boxall, R., Censin, J. C., Ferreira, T. D. G. M., Pulit, S. L., Glastonbury, C. A., Laber, S., Millwood, I. Y., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/531004 · Cited by 3
Editorial commentary: A new era for preventive cardiology
Clarke, S. L. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.007 · Cited by 3
Functionally deficient UBOX5 variants and primary angle-closure glaucoma
Li, Z., Chng, W. L., Liu, Z., Do, T., Nakano, M., Chen, L. J., Loo, Y., Chan, A. S. Y., Topouzis, F., Nongpiur, M. E., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-62775-x · Cited by 2
Chen, P.-Y., Liou, J.-W., Wu, M., & Yen, J.-H. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48060592 · Cited by 2
Guijarro, C., & Ruilope, L. M. (2015) · Medicina Clínica · doi:10.1016/j.medcli.2015.04.007 · Cited by 2
Laufs, U. (2015) · Springer eBooks · doi:10.1007/978-3-319-20433-8_3 · Cited by 2
Epidemiology of Atherosclerotic Cardiovascular Disease
Hirahatake, K. M., Dicklin, M. R., & Maki, K. C. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_5 · Cited by 2
Cholestérol alimentaire et morbi/mortalité cardiovasculaire
Hansel, B., & Giral, P. (2015) · Cahiers de Nutrition et de Diététique · doi:10.1016/j.cnd.2015.03.004 · Cited by 2
Yoon, H., Lee, Y., Kim, S.-H., Kim, E., Lee, H. H., & Jang, S. (2023) · International Journal of Modelling and Simulation · doi:10.1080/02286203.2023.2265543 · Cited by 2
Asl, S. K., Rahimzadegan, M., & Asl, A. K. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e28983 · Cited by 2
Wang, G., Zhang, L., Liang, G., Cao, Z., & Tang, Q. (2021) · Science of Advanced Materials · doi:10.1166/sam.2021.3920 · Cited by 2
Diabetes Mellitus and Intestinal Niemann-Pick C1–Like 1 Gene Expression
Malhotra, P., Gill, R. K., Dudeja, P. K., & Alrefai, W. A. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-801585-8.00022-1 · Cited by 2
Yuan, Q., Fu, Z.-Y., Wei, J. N., Li, P., Miao, H., Qu, Y.-X., Xu, J., Qin, J., Li, B.-L., Song, B., et al. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.09.164 · Cited by 2
OBSOLETE: Bioinformatics Principles for Deciphering Cardiovascular Diseases
Yang, X. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99576-x · Cited by 2
MicroRNA Regulation of HDL Homeostasis
Sun, X., & Feinberg, M. W. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-812513-7.00010-0 · Cited by 2
15. Phytosterol consumption and coronary artery disease
Simonen, P. P., Sittiwet, C., Nissinen, M. J., & Gylling, H. K. (2017) · Wageningen Academic Publishers eBooks · doi:10.3920/978-90-8686-853-7_15 · Cited by 2
Medikamentöse Therapie kardiologischer Erkrankungen im Alter
Schwinger, R. H. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0043-108475 · Cited by 2
Dayspring, T. D., & Pokrywka, G. S. (2020) · Contemporary cardiology · doi:10.1007/978-3-030-56514-5_13 · Cited by 2
Li, Y., Li, J., Tang, X., Xu, J., Liu, R., Jiang, L., Tian, J., Zhang, Y., Wang, D., Sun, K., et al. (2024) · BMC Medical Genomics · doi:10.1186/s12920-024-01802-0 · Cited by 2
ASGR1 - a new target for lowering non-HDL cholesterol
Hassan, M. S., & Wagdy, K. (2016) · Global Cardiology Science and Practice · doi:10.21542/gcsp.2016.14 · Cited by 2
Strategies for the use of nonstatin therapies
Pirillo, A., Norata, G. D., & Catapano, A. L. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000459 · Cited by 2
Genomics to Predict Risk of Coronary Artery Disease
Kessler, T., von Ameln, S., & Schunkert, H. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00002-0 · Cited by 2
Yamanashi, Y. (2019) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.19-00136 · Cited by 2
Chowdhury, R., Noh, M. F. M., Ismail, S. R., van Daalen, K. R., Kamaruddin, P. S. N. M., Zulkiply, S. H., Azizul, N. H., Khalid, N. M., Ali, A., Idris, I. M., et al. (2021) · JMIR Research Protocols · doi:10.2196/31885 · Cited by 2
Genetic Variation in NPC1L1 and Risk of Gallstone Disease
Lauridsen, B. K., Stender, S., & Tybjærg‐Hansen, A. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.05.076 · Cited by 2
Next Generation of Genotype Imputation Methods
Das, S. (2017) · Deep Blue (University of Michigan) · Cited by 2
Simonen, P. P., Wester, I., Lommi, J., Sinisalo, J. P., & Gylling, H. K. (2025) · Journal of Internal Medicine · doi:10.1111/joim.70031 · Cited by 1
Simonen, P. P., Lääperi, M., Ulander, L., Sinisalo, J. P., & Gylling, H. (2025) · Journal of Lipid Research · doi:10.1016/j.jlr.2025.100974 · Cited by 2
Primärprävention der koronaren Herzkrankheit
Mühleck, F., & Laufs, U. (2019) · Herz · doi:10.1007/s00059-019-04873-3 · Cited by 1
Cholesin and GPR146 in Modulating Cholesterol Biosynthesis
Kim, J., & Kim, Y. J. (2024) · Pharmacology · doi:10.1159/000540351 · Cited by 1
An interracial Mendelian analysis revealed a link between lipid‐lowering drugs and renal failure
Zhang, N., Ji, C., Xie, B., Liu, Y., & Yuan, C. (2025) · Lipids · doi:10.1002/lipd.12430 · Cited by 1
Rolle der Genetik in der Präzisionsmedizin der koronaren Herzkrankheit
Sanin, V., Schmieder, R., Köenig, W., Li, L., Schunkert, H., & Chen, Z. (2025) · Herz · doi:10.1007/s00059-025-05297-y · Cited by 1
Using inactivating mutations to provide insight into drug action
Corbin, L. J., & Timpson, N. J. (2015) · Genome Medicine · doi:10.1186/s13073-015-0130-x · Cited by 1
JCL roundtable: Lessons from genetic variants altering lipoprotein metabolism
Brown, W. V., Ference, B. A., & Kathiresan, S. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.002 · Cited by 1
Korszerű lipidcsökkentő kezelés
Paragh, G., & Karádi, I. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30505 · Cited by 1
Rare monogenic disorders of cholesterol metabolism
Bednarska‐Makaruk, M., & Ługowska, A. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85857-1.00024-9 · Cited by 2
Zebrafish Model for Drug Discovery and Screening
Joshi, S. (2022) · Springer eBooks · doi:10.1007/978-981-16-5217-2_11 · Cited by 1
Precision Medicine in Cardiovascular Disease Practice
Sheikhy, A., Fallahzadeh, A., Meybodi, H. R. A., & Hosseini, K. (2022) · Springer eBooks · doi:10.1007/978-981-19-5082-7_4 · Cited by 1
Catapano, A. L. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88286-6.00013-3 · Cited by 1
Costa, L. V., Caporossi, A., Enes, M. S. W., de Freitas, V. K., & Bomfim, V. V. B. D. S. (2023) · Revista Ibero-Americana de Humanidades, Ciências e Educação · doi:10.51891/rease.v9i10.12422 · Cited by 1
Li, B., Zhou, W., Yu, Y., Chen, B., Lv, Z., Zhang, J., Zhang, T., Sun, S., Zhou, L., & Wang, M. (2025) · FASEB BioAdvances · doi:10.1096/fba.2025-00044 · Cited by 1
A paradigm shift in the treatment of atherosclerosis
Ferrières, J. (2015) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2015.05.007 · Cited by 1
Advances in Hypercholesterolemia
Pirillo, A., Norata, G. D., & Catapano, A. L. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-409547-2.12435-7 · Cited by 1
Lipids in Coronary Heart Disease
Martin, S. S., Joshi, P. H., & Michos, E. D. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802385-3.00007-3 · Cited by 2
Genetics and Genomics of Coronary Artery Disease
Yamada, Y., & Yasukochi, Y. (2018) · Springer eBooks · doi:10.1007/978-3-319-66114-8_22 · Cited by 1
Ishibashi, Y., Karino, K., Yano, S., Kijima, T., Takahashi, N., Yamagata, S., KUROKOUCHI, K., Nagami, H., Honda, S., & Nosou, Y. (2018) · Vascular Failure · doi:10.30548/vascfail.2.1_20 · Cited by 1
Genetics and Genomics of Atherosclerotic Cardiovascular Disease
Musunuru, K., Qasim, A., & Reilly, M. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812532-8.00007-0 · Cited by 2
Self Nanoemulsifying Drug Delivery System: A Comrhensive Review
Anuja, G. G., Atram, S. C., Rupali, S. P., Vrunda, R. J., & Subhod, U. A. (2024) · Asian Journal of Pharmaceutical Research and Development · doi:10.22270/ajprd.v12i1.1354 · Cited by 1
Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Frishman, W. H. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.06.027 · Cited by 1
Ezetimibe–Statin Combination to Reduce Cardiovascular Events: The Evidence Base
Jialal, I., & Abate, N. I. (2015) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2015.29000.jia · Cited by 1
Roden, D. M. (2017) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2017.05.008 · Cited by 1
The Genetics of Coronary Heart Disease
Erdmann, J., & Venegas, M. L. M. (2019) · Cardiac and vascular biology · doi:10.1007/978-3-030-27371-2_4 · Cited by 1
Variant Validity (Selected vs. General Population)
Scientific, T. F., Billings, P. R., Raghavachari, N., & Senthil, G. (2015) · NAM Perspectives · doi:10.31478/201506a
PHYSIOLOGICAL MODULATION OF THE REVERSE CHOLESTEROL TRANSPORT PATHWAY IN VIVO
Silvennoinen, R. (2015) · Työväentutkimus Vuosikirja
Drug trial supports importance of low cholesterol to treat heart disease
Ledford, H. K. (2014) · Nature · doi:10.1038/nature.2014.16360
Cholesterol-absorbed in thought
Tietge, U. J. F. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000283
Leopold, J. A. (2016) · Coronary Artery Disease · doi:10.1097/mca.0000000000000367
Moderne Lipid-Therapie heute und morgen: Anti-PCSK9
Erbel, R., & Gitt, A. K. (2016) · Herz · doi:10.1007/s00059-016-4442-4
Modell zum individualisierten Lipidmanagement
Weingärtner, O., Lütjohann, D., & Elsässer, A. (2016) · Der Kardiologe · doi:10.1007/s12181-016-0054-8
Sensing and Remembering Cellular States Through Chromatin
Jiang, S., & Vondriska, T. M. (2016) · Springer eBooks · doi:10.1007/978-3-319-31828-8_15
Ézétimibe : plus de preuves pour un effet sur la réduction du risque cardiovasculaire
Vergès, B. L. (2016) · Médecine des Maladies Métaboliques · doi:10.1016/s1957-2557(16)30142-0
Editiorial Commentary: Genomics and drug discovery: The next frontier in precision medicine
Roden, D. M. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.09.004
Vogt, A. (2017) · Der Internist · doi:10.1007/s00108-016-0179-7
Guijarro, C., & Ruilope, L. M. (2015) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2015.04.002
Coronary Artery Disease and Myocardial Infarction
Assimes, T. L. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-800685-6.00008-4
Yamanashi, Y., Takada, T., & SUZUKI, H. (2017) · Japanese Journal of Thrombosis and Hemostasis · doi:10.2491/jjsth.28.345
Metabolismo del colesterol y mecanismos de acción de los fármacos hipolipemiantes
Canals, J. (2017) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2017.02.003
Identification of genetic modifiers in LRRK2 parkinsonism
Trinh, J. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0340339
The shape of things to come in lipid management: a feast of reason
Watts, G. F., & Stroes, E. S. G. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000467
Xenosterolemia: emerging molecular and clinical insights
Kane, J. P., Schaefer, E. J., & Malloy, M. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000463
Novel Approaches to Cardiovascular Diagnostics
Wingrove, J. A., & Rosenberg, S. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801812-5.00011-1
VIII. Development of New Strategy and Modality of Lipid Management
Okazaki, H. (2017) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.106.735
PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Status and Protection Against Ischemic Stroke
Sullivan, D., Bonnitcha, P., Spinks, C., & Keech, T. (2018) · Circulation Genomic and Precision Medicine · doi:10.1161/circgen.118.002247
Kathiresan, S. (2019) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2019.02.011
Cardiovascular primary prevention – directed approach for individual features
Mano, T. B., Rosa, S. A., Rio, P., Timóteo, A. T., & Ferreira, R. C. (2019) · Portuguese Journal of Nephrology & Hypertension · doi:10.32932/pjnh.2019.07.022
Novel Therapies for Dyslipidemia
Tafaj-Reddy, O. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.88477
Encouragement of Super-aggressive LDL-lowering Therapies
Tada, H., Sakata, K., Takamura, M., & Kawashiri, M. (2019) · Journal of Coronary Artery Disease · doi:10.7793/jcad.25.19-00005
The role of carotid artery disease in ischaemic stroke
Ball, S. (2019) · Research Explorer (The University of Manchester)
Assessing the efficacy and safety of angiotensinogen inhibition using human geneticsPreprint
Bovijn, J., Censin, J. C., Lindgren, C. M., & Holmes, M. V. (2020) · medRxiv · doi:10.1101/2020.08.13.20174094
Nakano, T., Inoue, I., & Murakoshi, T. (2018) · Preprints.org · doi:10.20944/preprints201809.0345.v1
Metadata
- Authors
- The Myocardial Infarction Genetics Consortium Investigators
- Affiliations
- Washington University in St. Louis (US)
- Corresponding author
- The Myocardial Infarction Genetics Consortium Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-11-27
- Volume
- 371
- Issue
- 22
- Pages
- 2072-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4335708
- OpenAlex
- W2478496979
- Cited by
- 419
- References
- 41
- Citations by year
- 2026: 8 · 2025: 12 · 2024: 13 · 2023: 21 · 2022: 19 · 2021: 26 · 2020: 36 · 2019: 44 · 2018: 31 · 2017: 47 · 2016: 84 · 2015: 73 · 2014: 5
- FWCI
- 69.04
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Discovery Research Portal (University of Dundee) (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- mediaTUM (Technical University of Munich) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0512-10165)
- British Heart Foundation (RG/08/014/24067)
- National Institutes of Health (UL1TR000124)
- Canadian Institutes of Health Research
- Medical Research Council (MR/L003120/1)
- National Institute on Aging (U01AG049505)
- National Heart, Lung, and Blood Institute (RC2HL102925, K08HL114642, RC2HL102926, R01HL107816, T32HL007208)
- National Human Genome Research Institute (U54HG003067, U01HG006378)
- National Cancer Institute (R01CA082659)
- National Institute of Nursing Research (R01NR013396)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK063491)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- NPC1L1, loss-of-function mutations, coronary artery disease, ezetimibe, LDL cholesterol, plasma lipids, genetic variants, therapeutic target, LDL cholesterol lowering
- MeSH terms
- Adult, Coronary Disease, Exons, Female, Genotype, Humans, Cholesterol, LDL, Male, Membrane Proteins, Middle Aged, Mutation, Protein Conformation, Risk, Triglycerides, Case-Control Studies, Sequence Analysis, DNA, Gene Silencing, Membrane Transport Proteins, Black People, White People, Asian People
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
